Aim: To compare access to new prescription-only medicines in New Zealand (NZ) with that in Australia.

Method: The range of new prescription medicines and the timing of their regulatory approval and reimbursement in NZ and Australia in the period 2000 to 2009 were compared.

Results: 136 new prescription medicines were first listed in the Australian Schedule of Pharmaceutical Benefits in the study period and 59 (43%) of these were listed in the NZ Pharmaceutical Schedule. Listing of these 59 medicines for reimbursement occurred later in NZ (mean difference=32.7 months; 95% CI 24.2 to 41.2 months; p<0.0001) due largely to a longer time from registration to listing (mean difference=23.7 months; 95% CI 14.9 to 32.4 months; p<0.0001). The remaining 77 medicines that are reimbursed in Australia but not in NZ cover a wide range of therapeutic areas, including some diseases for which there are no reimbursed medicines in NZ. Four new medicines were listed in NZ but not Australia.

Conclusion: In the last decade, public access to new medicines in NZ has been more limited and delayed compared to Australia.

Download full-text PDF

Source

Publication Analysis

Top Keywords

medicines zealand
8
prescription medicines
8
access medicines
4
zealand compared
4
compared australia
4
australia aim
4
aim compare
4
compare access
4
access prescription-only
4
medicines
4

Similar Publications

Objective: This study investigated the association between loss of MSH2/MSH6 versus loss of MLH1/PMS2 expression and overall survival and disease-free survival in patients with localized colorectal cancer.

Background: The risk of developing colorectal cancer varies depending on the expression of mismatch repair proteins. However, it is unknown if the prognosis differs accordingly.

View Article and Find Full Text PDF

Background: We aimed to investigate if iron deficiency was associated with infection susceptibility in a large cohort of healthy individuals.

Study Design And Methods: The Danish Blood Donor Study is a national ongoing prospective study of blood donors. We included 94,628 donors with 338,290 ferritin measurements from March 2010 to October 2022.

View Article and Find Full Text PDF

Introduction: A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients to distinguish these from higher risk invasive melanomas. This study aims to explore whether using an alternative label for melanoma in situ may influence patients' management choices and anxiety levels.

Methods And Analysis: This study is a between-subjects randomised online experiment, using hypothetical scenarios.

View Article and Find Full Text PDF

Introduction: Infants born very preterm (VPT, <32 weeks' gestation) are at increased risk for neurodevelopmental impairments including motor, cognitive and behavioural delay. Parents of infants born VPT also have poorer mental health outcomes compared with parents of infants born at term.We have developed an intervention programme called TEDI-Prem (Telehealth for Early Developmental Intervention in babies born very preterm) based on previous research.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!